The rapid process of research and development and lack of follow-up time post-vaccination aroused greater public concern about the safety profile of COVID-19 vaccine candidates. Pharmacovigilance is critical for gathering, recognising, and monitoring adverse events, which is the primary goal. The reported adverse events should be evaluated to determine the causal relationship and avoid unnecessary consequences on the recipient. Many people are getting vaccines in a short period of time, putting a strain on pharmacovigilance facilities. The International Society of Pharmacovigilance (ISOP), the French National Agency for Medicines and Health Products Safety (ANSM), and many others worked together and took many initiatives to determine the safety and efficacy of vaccines, as well as to provide answers to the questions that were raised. Signals were discovered and several adverse occurrences were identified thanks to pharmacovigilance. BioNTech/Pfizer-m-RNA, Moderna-mRNA vaccine, Covishield, Johnson and Johnson, Vaxzervria, Sputnik V, and Convidicea pharmacovigilance is discussed. There were 12,249 ADRs reported with BioNTech/Pfizer-mRNA, 577 ADRs with Moderna-mRNA vaccine, 447 ADRs with Covishield, 653 ADRs with Johnson and Johnson, and 743 ADRs with Vaxzervria. As a result of these immunizations, Immune thrombocytopenic purpura, cerebrovascular events, thrombosis, thrombocytopenia, facial paralysis, fatalities, and a variety of other potentially lethal reactions have all been linked to these immunizations. However, the recorded incidents were minor in comparison to the patients' safety. The Uppsala monitoring centre kept track of all of these events. Uppsala monitoring centre, an initiative of WHO to detect various ADR relating to medications and preventing serious causalities associating with it have a greater role in minimizing the serious cases occurs with medicine dysfunction.